Профилактика коронавирусной инфекции covid-19 путем Использования зубной пасты colgate, содержащий цинк

  • № 4 2021

Страницы: 

648

 – 

660

Язык: русский

Открыть файл статьи
Открыть страницу статьи в Интернет

Аннотация

В данном обзоре представлены данные по известной зубной пасте Colgat, о составе и влиянии на течение коронавирусной инфекции COVID-19. Также описаны ополаскиватели на основе поливидона йода, который эффективно устраняет и нейтрализует коронавирусную инфекцию в полости рта. Представлены данные о строении коронавируса ипутей патогенеза влияния его на систему местного иммунитета полости рта. Также прдставлен известный антиспетик хлоргексидин и его эффективность против коронавирусной инфекции.

This review presents data on the famous Colgat toothpaste, on the composition and effect on the course of coronavirus infection COVID-19. Also described are rinses based on polyvidone iodine, which effectively eliminates and neutralizes coronavirus infection in the oral cavity. Data on the structure of the coronavirus and the pathways of its pathogenesis of its influence on the local immunity system of the oral cavity are presented. Also presented is the well-known antispecialty chlorhexidine and its effectiveness against coronavirus infection.

Список использованных источников

  1. World Health Organization (2020) Coronavirus disease 2019 (COVID-19) situation report – 99
  2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  3. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. [PubMed] [CrossRef] [Google Scholar]
  4. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,retrospective, observational study. Lancet Respir Med. 2020;8:475–481. doi: 10.1016/S2213-2600(20)30079-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  5. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y,Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.JAMA Intern Med. 10.1001/jamainternmed.2020.0994 [PMC free article] [PubMed]
  6. Sanz M, Ceriello A, Buysschaert M, Chapple I, Demmer RT, Graziani F, Herrera D, Jepsen S, Lione L, Madianos P,Mathur M, Montanya E, Shapira L, Tonetti M, Vegh D. Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. J Clin Periodontol. 2018;45(2):138–149. doi: 10.1111/jcpe.12808. [PubMed] [CrossRef] [Google Scholar]
  7. Sanz M, Marco del Castillo A, Jepsen S, Gonzalez-Juanatey JR, D’Aiuto F, Bouchard P, Chapple I, Dietrich T, Gotsman I, Graziani F, Herrera D, Loos B, Madianos P, Michel J-B, Perel P, Pieske B, Shapira L, Shechter M, Tonetti M,Vlachopoulos C, Wimmer G (2019) Periodontitis and cardiovascular diseases: consensus report. J Clin Periodontol In press.
  8. Tonetti MS, Jepsen S, Jin L, Otomo-Corgel J. Impact of the global burden of periodontal diseases on health, nutrition and wellbeing of mankind: a call for global action. J Clin Periodontol. 2017;44(5):456–462. doi:10.1111/jcpe.12732. [PubMed] [CrossRef] [Google Scholar]
  9. Herrera D, Sanz M, Herrera Pombo JL, Gomez Doblas JJ, Guerrero A. Oral health also matters. Semergen. 2016;42(4):213–215. doi: 10.1016/j.semerg.2016.04.009. [PubMed] [CrossRef] [Google Scholar]
  10. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi: 10.1038/s41368-020-0074-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  11. Xu J, Li Y, Gan F, Du Y, Yao Y (2020) Salivary glands: potential reservoirs for COVID-19 asymptomatic infection. J Dent Res:22034520918518. 10.1177/0022034520918518 [PubMed]
  12. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–469. doi: 10.1038/s41586-020-2196-x. [PubMed] [CrossRef] [Google Scholar]
  13. Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: potential diagnostic value and transmission of 2019-nCoV. Int J Oral Sci. 2020;12(1):11. doi: 10.1038/s41368-020-0080-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  14. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, Peiris M, Poon LLM, Zhang W. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20:656–657. doi: 10.1016/S1473-3099(20)30232-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  15. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368:860–868. doi: 10.1126/science.abb5793. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  16. Ren YF, Rasubala L, Malmstrom H, Eliav E (2020) Dental care and oral health under the clouds of COVID-19. JDR Clin Trans Res:2380084420924385. 10.1177/2380084420924385 [PubMed]
  17. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(1):9. doi: 10.1038/s41368-020-0075-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  18. Logothetis DD, Martinez-Welles JM. Reducing bacterial aerosol contamination with a chlorhexidine gluconate prerinse.J Am Dent Assoc. 1995;126(12):1634–1639. doi: 10.14219/jada.archive.1995.0111. [PubMed] [CrossRef] [Google Scholar]
  19. Stirrups DR. Methods of reducing bacterial contamination of the atmosphere arising from use of an air-polisher. Br Dent J. 1987;163(7):215–216. doi: 10.1038/sj.bdj.4806253. [PubMed] [CrossRef] [Google Scholar]
  20. Worrall SF, Knibbs PJ, Glenwright HD. Methods of reducing bacterial contamination of the atmosphere arising from use of an air-polisher. Br Dent J. 1987;163(4):118–119. doi: 10.1038/sj.bdj.4806212. [PubMed] [CrossRef] [Google Scholar]
  21. Fine DH, Yip J, Furgang D, Barnett ML, Olshan AM, Vincent JW. Reducing bacteria in dental aerosols: procedural use of an antiseptic mouthrinse. J Am Dent Assoc. 1993;124(10):16–18. doi: 10.14219/jada.archive.1993.0202. [PubMed] [CrossRef] [Google Scholar]
  22. Marui VC, Souto MLS, Rovai ES, Romito GA, Chambrone L, Pannuti CM. Efficacy of preprocedural mouthrinses in the reduction of microorganisms in aerosol: a systematic review. J Am Dent Assoc. 2019;150(12):1015–1026. doi:10.1016/j.adaj.2019.06.024. [PubMed] [CrossRef] [Google Scholar]
  23. Addy M, Wright R. Comparison of the in vivo and in vitro antibacterial properties of providone iodine and chlorhexidine gluconate mouthrinses. J Clin Periodontol. 1978;5(3):198–205. doi: 10.1111/j.1600-051x.1978.tb02280.x. [PubMed][CrossRef] [Google Scholar]
  24. Eggers M. Infectious disease management and control with povidone iodine. Infect Dis Ther. 2019;8(4):581–593. doi:10.1007/s40121-019-00260-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  25. Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA) Infect Dis Ther. 2015;4(4):491–501. doi: 10.1007/s40121-015-0091-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  26. Eggers M, Koburger-Janssen T, Ward LS, Newby C, Muller S. Bactericidal and virucidal activity of povidone-iodine and chlorhexidine gluconate cleansers in an in vivo hand hygiene clinical simulation study. Infect Dis Ther. 2018;7(2):235–247. doi: 10.1007/s40121-018-0202-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  27. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther. 2018;7(2):249–259. doi: 10.1007/s40121- 018-0200-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  28. Kanagalingam J, Feliciano R, Hah JH, Labib H, Le TA, Lin JC. Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections. Int J Clin Pract. 2015;69(11):1247–1256. doi: 10.1111/ijcp.12707. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  29. Kawana R, Kitamura T, Nakagomi O, Matsumoto I, Arita M, Yoshihara N, Yanagi K, Yamada A, Morita O, Yoshida Y, Furuya Y, Chiba S. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatology. 1997;195(Suppl 2):29–35. doi: 10.1159/000246027. [PubMed] [CrossRef] [Google Scholar]
  30. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology. 2006;212(Suppl 1):119–123. doi: 10.1159/000089211. [PMC free article] [PubMed][CrossRef] [Google Scholar]
  31. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions,and chemical reagents. Jpn J Vet Res. 2004;52(3):105–112. [PubMed] [Google Scholar]
  32. Ito H, Ito T, Hikida M, Yashiro J, Otsuka A, Kida H, Otsuki K. Outbreak of highly pathogenic avian influenza in Japan and anti-influenza virus activity of povidone-iodine products. Dermatology. 2006;212(Suppl 1):115–118. doi:10.1159/000089210. [PubMed] [CrossRef] [Google Scholar]
  33. Ito H, Hikida M, Yashiro J. Virucidal efficacy of povidone-iodine products against swine influenza viruses. Jap J Chemother. 2009;57(6):508–510. [Google Scholar]
  34. Costa X, Laguna E, Herrera D, Serrano J, Alonso B, Sanz M. Efficacy of a new mouth rinse formulation based on 0.07% cetylpyridinium chloride in the control of plaque and gingivitis: a 6-month randomized clinical trial. J Clin Periodontol. 2013;40(11):1007–1015. doi: 10.1111/jcpe.12158. [PubMed] [CrossRef] [Google Scholar]
  35. Figuero E, Herrera D, Tobias A, Serrano J, Roldan S, Escribano M, Martin C. Efficacy of adjunctive anti-plaque chemical agents in managing gingivitis: a systematic review and network meta-analyses. J Clin Periodontol. 2019;46(7):723–739. doi: 10.1111/jcpe.13127. [PubMed] [CrossRef] [Google Scholar]
  36. Escribano M, Figuero E, Martin C, Tobias A, Serrano J, Roldan S, Herrera D. Efficacy of adjunctive anti-plaque chemical agents: a systematic review and network meta-analyses of the Turesky modification of the Quigley and Hein plaque index. J Clin Periodontol. 2016;43(12):1059–1073. doi: 10.1111/jcpe.12616. [PubMed] [CrossRef] [Google Scholar]
  37. Serrano J, Escribano M, Roldan S, Martin C, Herrera D. Efficacy of adjunctive anti-plaque chemical agents in managing gingivitis: a systematic review and meta-analysis. J Clin Periodontol. 2015;42(Suppl 16):S106–S138. doi:10.1111/jcpe.12331. [PubMed] [CrossRef] [Google Scholar]
  38. Popkin DL, Zilka S, Dimaano M, Fujioka H, Rackley C, Salata R, Griffith A, Mukherjee PK, Ghannoum MA, Esper F.Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against influenza viruses in vitro and in vivo. Pathog Immun. 2017;2(2):252–269. doi: 10.20411/pai.v2i2.200. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  39. Mukherjee PK, Esper F, Buchheit K, Arters K, Adkins I, Ghannoum MA, Salata RA. Randomized, double-blind,placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect Dis. 2017;17(1):74. doi: 10.1186/s12879-016-2177-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  40. Shen L, Niu J, Wang C, Huang B, Wang W, Zhu N, Deng Y, Wang H, Ye F, Cen S, Tan W (2019) High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. J Virol 93(12). 10.1128/JVI.00023-19 [PMC free article] [PubMed]
  41. Herrera D, Roldan S, Santacruz I, Santos S, Masdevall M, Sanz M. Differences in antimicrobial activity of four commercial 0.12% chlorhexidine mouthrinse formulations: an in vitro contact test and salivary bacterial counts study. J Clin Periodontol. 2003;30(4):307–314. doi: 10.1034/j.1600-051x.2003.00341.x. [PubMed] [CrossRef] [Google Scholar]
  42. Roldan S, Winkel EG, Herrera D, Sanz M, Van Winkelhoff AJ. The effects of a new mouthrinse containing chlorhexidine, cetylpyridinium chloride and zinc lactate on the microflora of oral halitosis patients: a dual-centre, doubleblind placebo-controlled study. J Clin Periodontol. 2003;30(5):427–434. doi: 10.1034/j.1600-051x.2003.20004.x. [PubMed] [CrossRef] [Google Scholar]
  43. Garcia-Gargallo M, Zurlohe M, Montero E, Alonso B, Serrano J, Sanz M, Herrera D. Evaluation of new chlorhexidineand cetylpyridinium chloride-based mouthrinse formulations adjunctive to scaling and root planing: pilot study. Int J Dent Hyg. 2017;15(4):269–279. doi: 10.1111/idh.12254. [PubMed] [CrossRef] [Google Scholar]
  44. Escribano M, Herrera D, Morante S, Teughels W, Quirynen M, Sanz M. Efficacy of a low-concentration chlorhexidine mouth rinse in non-compliant periodontitis patients attending a supportive periodontal care programme: a randomized clinical trial. J Clin Periodontol. 2010;37(3):266–275. doi: 10.1111/j.1600-051X.2009.01521.x. [PubMed] [CrossRef] [Google Scholar]
  45. Pulcini A, Bollain J, Sanz-Sanchez I, Figuero E, Alonso B, Sanz M, Herrera D. Clinical effects of the adjunctive use of a 0.03% chlorhexidine and 0.05% cetylpyridinium chloride mouth rinse in the management of peri-implant diseases: a randomized clinical trial. J Clin Periodontol. 2019;46(3):342–353. doi: 10.1111/jcpe.13088. [PubMed] [CrossRef] [Google Scholar]
  46. An N, Yue L, Zhao B. Droplets and aerosols in dental clinics and prevention and control measures of infection. Zhonghua Kou Qiang Yi Xue Za Zhi. 2020;55(0):E004. doi: 10.3760/cma.j.cn112144-20200221-00081. [PubMed] [CrossRef] [Google Scholar]
  47. Su J. Aerosol transmission risk and comprehensive prevention and control strategy in dental treatment. Zhonghua Kou Qiang Yi Xue Za Zhi. 2020;55(0):E006. doi: 10.3760/cma.j.cn112144-20200303-00112. [PubMed] [CrossRef] [Google Scholar]
  48. Karpinski TM, Szkaradkiewicz AK. Chlorhexidine--pharmaco-biological activity and application. Eur Rev Med Pharmacol Sci. 2015;19(7):1321–1326. [PubMed] [Google Scholar]
  49. Lafaurie GI, Zaror C, Diaz-Baez D, Castillo DM, De Avila J, Trujillo TG, Calderon-Mendoza J. Evaluation of substantivity of hypochlorous acid as an antiplaque agent: a randomized controlled trial. Int J Dent Hyg. 2018;16(4):527–534. doi: 10.1111/idh.12342. [PubMed] [CrossRef] [Google Scholar]
  50. Hossainian N, Slot DE, Afennich F, Van der Weijden GA. The effects of hydrogen peroxide mouthwashes on the prevention of plaque and gingival inflammation: a systematic review. Int J Dent Hyg. 2011;9(3):171–181. doi:10.1111/j.1601-5037.2010.00492.x. [PubMed] [CrossRef] [Google Scholar]
  51. Meiller TF, Silva A, Ferreira SM, Jabra-Rizk MA, Kelley JI, DePaola LG. Efficacy of Listerine antiseptic in reducing viral contamination of saliva. J Clin Periodontol. 2005;32(4):341–346. doi: 10.1111/j.1600-051X.2005.00673.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  52. Carrouel F, Conte MP, Fisher J, Goncalves LS, Dussart C, Llodra JC, Bourgeois D (2020) COVID-19: a recommendation to examine the effect of mouthrinses with beta-cyclodextrin combined with Citrox in preventing infection and progression. J Clin Med 9(4). 10.3390/jcm9041126 [PMC free article] [PubMed]
  53. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251. doi: 10.1016/j.jhin.2020.01.022. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  54. Chin AWH, Chu JTS, Perera MRA, Hui KPY, Yen H-L, Chan MCW, Peiris M, Poon LLM (2020) Stability of SARSCoV-2 in different environmental conditions. Lancet Microbe (published online April 2) [PMC free article] [PubMed]

Список всех публикаций, цитирующих данную статью